Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: 480 mg PF-06473871; Drug: 320 mg PF-06473871; Drug: 80 mg PF-06473871; Drug: 160 mg PF-06473871

Study type: Interventional

Funder types: Industry

Identifiers

NCT01753791

2012-003797-13 (EudraCT Number)

B5301002

Details and patient eligibility

About

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06473871 in normal healthy adults.

Enrollment: 32 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and/or females between the ages of 18 and 55 years inclusive

Exclusion criteria

• Currently pregnant

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

32 participants in 4 patient groups

Cohort 1

Experimental group

Treatment:

Drug: 80 mg PF-06473871

Cohort 2

Experimental group

Treatment:

Drug: 160 mg PF-06473871

Cohort 3

Experimental group

Treatment:

Drug: 320 mg PF-06473871

Cohort 4

Experimental group

Treatment:

Drug: 480 mg PF-06473871